AB Science S.A.

AB Science is a French pharmaceutical company founded in 2001 and headquartered in Paris, France. The company specializes in the research, discovery, development, and commercialization of innovative drugs, primarily protein kinase inhibitors (PKIs), targeting diseases with high unmet medical needs in both human and veterinary medicine.

AB Science's pipeline is centered around two main compounds: masitinib, a selective tyrosine kinase inhibitor, and AB8939, a new generation microtubule destabilizer. Masitinib is being developed across various therapeutic areas, including oncology, inflammatory diseases, and neurological degenerative disorders such as Amyotrophic Lateral Sclerosis (ALS), progressive forms of multiple sclerosis, Alzheimer's Disease, indolent severe systemic mastocytosis, severe asthma, and sickle cell disease. The company also markets Masivet®, a masitinib-based product registered for veterinary use in canine mast cell tumors.

Recent developments for AB Science include securing a clinical trial funding insurance for its Phase III ALS trial and recent capital increases. The company has also announced the identification of a plasma biomarker for masitinib in ALS and received patent allowances for masitinib in prostate cancer and multiple sclerosis. Alain Moussy serves as the Co-founder, Chairman, and Chief Executive Officer. The company is currently reviewing its strategic priorities, including deprioritizing certain mastocytosis and mast cell activation programs, following discussions with European health authorities regarding resources for clinical studies.

Latest updates

AB Science Secures €3.2 Million Private Placement to Advance AB8939 Development

Event summary

  • AB Science completed a €3.2 million private placement subscribed to by a limited number of investors.
  • The placement involved the issuance of 3,412,768 new ordinary shares with warrants (BSAs), priced at a 17.53% discount to the 3-day VWAP.
  • Proceeds will primarily fund the clinical development of the AB8939 program.
  • The company has imposed lock-up commitments on existing shareholders and directors/officers.
  • New shares are expected to begin trading on Euronext Paris on May 5, 2026.

The big picture

This private placement addresses AB Science’s immediate financing needs, but the discounted share price and warrant issuance signal investor caution regarding the company’s pipeline and overall valuation. The reliance on private placements, rather than public offerings, suggests challenges in accessing broader capital markets. The focus on AB8939 development highlights a strategic pivot towards oncology, potentially shifting away from broader therapeutic areas.

What we're watching

Clinical Progress
The success of AB8939’s clinical trials will be critical to justifying the capital raise and demonstrating a return on investment for new shareholders; early data releases will be closely scrutinized.
Shareholder Alignment
The lock-up commitments suggest concerns about potential share price volatility; whether these restrictions will be adhered to and their impact on trading dynamics warrants observation.
BSA Exercise
The potential for an additional €2.2 million through BSA exercise represents a contingent funding source, but the exercise rate will depend on investor confidence and future performance.

AB Science Secures Loan Restructuring, Eyes Phase III Trial Funding

Event summary

  • AB Science has reached a final agreement with its financial creditors to defer loan repayments.
  • The agreement includes a 24-month deferral on approximately €3.7 million in bank debt and a 12-month deferral on a €12 million EIB loan.
  • The restructuring involves interest rate adjustments and extended maturity dates for various loans, totaling approximately €18.95 million.
  • The company intends to allocate the resulting savings to R&D efforts, specifically supporting its Phase III clinical trial in amyotrophic lateral sclerosis.
  • Publication of AB Science’s annual report has been postponed to no later than May 13, 2026.

The big picture

AB Science's loan restructuring highlights the ongoing challenges faced by smaller biotech firms reliant on external funding, particularly those with late-stage clinical programs. The agreement, while providing short-term relief, underscores the company's vulnerability to clinical trial outcomes and the need for continued investor confidence. This type of restructuring is increasingly common as companies navigate volatile capital markets and the high costs of drug development.

What we're watching

Clinical Trial Success
The success of the Phase III trial in amyotrophic lateral sclerosis will be critical to justifying the restructured debt and attracting further investment, as repayment is tied to commercial success in some cases.
Cash Runway
While the restructuring extends the company’s cash runway, the ability to secure additional funding beyond the next 12 months remains contingent on positive clinical trial data and market reception.
Governance Dynamics
The unanimous agreement from creditors suggests a degree of confidence in AB Science’s strategy, but the postponed annual report raises questions about transparency and potential underlying financial concerns.
CID: 2014